CRP: What It Can, and Can't, Tell You

Key Takeaways

• hsCRP <1 low risk; 1‑3 average; >3 high cardiovascular risk
• ACC 2025 advises baseline hsCRP screening, not yearly repeats
• JUPITER showed rosuvastatin cut events 44% in high hsCRP, normal LDL
• USPSTF rates universal hsCRP testing as ‘I’—insufficient evidence
• Serial hsCRP tracking for supplements lacks evidence; single baseline suffices

Pulse Analysis

C‑reactive protein has long served as the body’s "smoke detector" for inflammation, but only the high‑sensitivity assay (hsCRP) can quantify the low‑grade inflammation linked to atherosclerosis. By measuring concentrations as low as 0.1 mg/L, clinicians can stratify patients into three risk buckets—low (<1 mg/L), average (1‑3 mg/L), and high (>3 mg/L). This granularity complements traditional lipid panels, offering a clearer picture of residual risk in individuals whose cholesterol numbers appear benign.

The 2025 ACC scientific statement endorses a single baseline hsCRP test for adults undergoing cardiovascular risk assessment, while the 2026 ACC/AHA dyslipidemia guideline assigns it a Class 2a recommendation for borderline‑risk patients. In contrast, the USPSTF assigns an "I" rating, citing insufficient evidence that universal screening improves outcomes. The landmark JUPITER trial cemented hsCRP’s clinical relevance: participants with hsCRP ≥2 mg/L and normal LDL experienced a 44% reduction in major cardiovascular events when treated with rosuvastatin, a benefit that held true across sexes. Yet subsequent FDA analyses suggest the advantage is confined to those with both elevated hsCRP and at least one traditional risk factor, tempering enthusiasm for blanket testing.

Despite its scientific merit, hsCRP has become a buzzword on social media, spawning a market for serial testing tied to supplements and diet plans. No longitudinal “treat‑to‑CRP” trials exist, and repeated measurements can mislead patients, especially women on oral hormone therapy where estrogen artificially inflates hsCRP without increasing true cardiovascular risk. Clinicians should reserve hsCRP for a one‑time risk‑enhancement tool, interpret results in the context of overall risk, and discourage consumers from paying for unnecessary repeat tests marketed as health hacks. This disciplined approach maximizes the test’s predictive power while protecting patients from costly, unsupported regimens.